Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 3/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 3/20 | 0.34 |
| ▸ | NOS1 | P29475 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14075048 | 0.81 | ASIC3 (0.38) | ASIC3DPP4KDM4EALDH1A1MEN1 | |
| SCHEMBL10160861 | 0.79 | ASIC3 (0.44) | ASIC3KDM4EALDH1A1MEN1MAPT | |
| SCHEMBL4309177 | 0.78 | ASIC3 (0.38) | ASIC3AGXTKDM4EALDH1A1MEN1 | |
| SCHEMBL4312364 | 0.78 | ASIC3 (0.43) | ASIC3KDM4EALDH1A1MEN1MAPT | |
| SCHEMBL563407 | 0.77 | KDM4E (0.58) | DPP4AGXTKDM4EALDH1A1MAPT | |
| SCHEMBL10130760 | 0.75 | IDH1 (0.46) | ASIC3KDM4EALDH1A1MEN1MAPT | |
| SCHEMBL4344143 | 0.74 | ASIC3 (0.46) | ASIC3KDM4EALDH1A1MEN1MAPT | |
| SCHEMBL4313732 | 0.71 | ALDH1A1 (0.55) | ASIC3KDM4EALDH1A1MEN1MAPT | |
| SCHEMBL4315196 | 0.70 | ASIC3 (0.39) | ASIC3KDM4EALDH1A1MEN1MAPT | |
| SCHEMBL4317083 | 0.70 | ASIC3 (0.39) | ASIC3IDH1NOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041618-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | ENANTA PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20100041618-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | ENANTA PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20080262208-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | WANG GUOQIANG | 2008-10-23 | — | — | US | disclosed |
| US-20080262208-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | WANG GUOQIANG | 2008-10-23 | — | — | US | disclosed |
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-7384922-B2 | 6-11 bridged oxime erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384922-B2 | 6-11 bridged oxime erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-7265094-B2 | 9N-substituted 6-11 bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265094-B2 | 9N-substituted 6-11 bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20060142214-A1 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
| WO-2005070113-A2 | 9N-SUBSTITUTED 6-11 BICYCLIC ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041618-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | CYP2D6, CYP2B6, CYP1B1 | ASIC3 2946/4885DPP4 767/4885AGXT 1956/4885 |
| US-20060142214-A1 | 3,6-bicyclolides | ABCB11, CYP2B6, CYP3A7 | ASIC3 640/4885DPP4 440/4885AGXT 1676/4885 |
| US-20080262208-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | CYP2D6, CYP2B6, CYP1B1 | ASIC3 2946/4885DPP4 767/4885AGXT 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.